RxDoctor Payments Data

Bryan Youree, MD

Infectious Disease · Fort Worth, TXNPI 1114014248

Payments from drug & device makers

$1,265in general payments, 2019–2025

Across 61 payments — averaging $20.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Viiv Healthcare Company$466
  • AbbVie$464
  • Cumberland Pharmaceuticals, Inc.$114
  • Johnson & Johnson$35
  • Gilead$34
  • Takeda Pharmaceuticals U.S.A., Inc.$30
  • plus $123 from 6 others

What the payments were for

  • Food & beverage$1,265100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,265 in reported general payments places this provider in the 60th percentile of 576 infectious disease providers in Texas.

See all infectious disease providers in Texas

Medicare billing

Part B allowed, 2024
$1,227,718
Medicare patients
684
Services billed
127,105

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala27$133,325
GammakedImmune Globul G/Gly/Iga Avg 4613$83,686
XembifyImmune Globulin,gamma(Igg)klhw22$75,550
TriumeqAbacavir/Dolutegravir/Lamivudi14$58,917
EdurantRilpivirine Hcl14$18,197
Vancomycin Hcl80$14,932
Daptomycin40$13,657
ErtapenemErtapenem Sodium31$12,256
Cefepime Hcl60$11,931
Cefazolin Sodium64$5,580
Piperacillin-TazobactamPiperacillin Sodium/Tazobactam22$5,164
Doxycycline Hyclate159$5,055
Cephalexin242$4,896
CeftriaxoneCeftriaxone Sodium74$4,692
Meropenem30$3,969

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy$34$133,32527 claims
Viiv Healthcare CompanyTriumeq$466$58,91714 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 576 infectious disease providers in Texas.

Other infectious disease in Fort Worth

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →